

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office: Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel.: 022-2407 2249 / 2401 9025 (30 Lines)

Fax: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com Website: www.aartidrugs.com

### STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2013

PART I (Rs. in lacs except fo Quarter Ended Nine Months Ended								
	Particulars	31st Dec 2013	Quarter Ended	31st Dec 2012			Year Ended	
Sr.	Particulars		30th Sep 2013		31st Dec 2013	31st Dec 2012	31st March 2013	
No.		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	
1	Income from Operations							
	(a) Gross Sales / Income from Operations	23,895	26,627	21,273	74,048	64,927	88,575	
	Less : Excise Duty & Sales Tax	1,719	1,847	1,424	5,234	4,461	6,091	
	(a) Net Sales / Income from Operations	22,176	24,780	19,849	68,814	60,466	82,484	
	(Net Of Excise Duty & Sales Tax)		200000000000000000000000000000000000000	C-650 AC 200	Gatheranten	( 05500000000		
	(b) Other Operating Income	40	15	65	61	73	91	
	Total income from operations (net)	22,215	24,795	19,913	68,875	60,539	82,575	
2	Expenditure							
	(a) Cost of materials consumed	11,874	16,453	11,255	41,415	36,379	49,244	
	(b) Purchase of stock-in-trade	1,800	2,564	2,161	6,847	6,486	8,543	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	644	(1,881)	(412)	(1,814)	(2,071)	(2,259	
	(d) Employee benefits expense	806	832	774	2.379	2.090	2.853	
	(e) Depreciation and Amortisation Expense	699	684	654	2.053	1,927	2,598	
	(f) Other expenses	3.347	3.307	3,157	9.683	9.144	12,16	
	Total expenses	19,170	21.958	17,590	60,561	53,955	73.140	
	Total experises	10,170	21,000	11,000	00,001	30,000	10,140	
3	Profit from Operations before Other Income,			1279120	600000000			
	finance costs and exceptional items (1-2)	3,045	2,837	2,324	8,314	6,585	9,435	
4	Other Income				-			
5	Profit from ordinary activities before finance cost	3,045	2,837	2,324	8,314	6,585	9,435	
	and exceptional items (3+4)	1000000	2082999	50000	2622729924	80000000		
6	Finance costs (interest)	924	780	749	2,432	2,048	2,804	
7	Profit from ordinary activities after finance cost	0.000.000.00	200000000	11000000	9,000,000	200000000		
	but before Exceptional Items (5-6)	2,121	2,057	1,574	5,882	4,537	6,631	
8	Exceptional Items	-			-	3.50	-	
9	Profit from Ordinary Activities before Tax (7-8)	2,121	2,057	1,574	5,882	4,537	6,631	
10	Tax Expenses	705	772	480	1,997	1,394	2,064	
	Provision for Taxation - Current	615	615	400	1,670	1,170	1,760	
	- Earlier year		67		67			
	Provision for Deferred Taxation	90	90	80	260	224	304	
11	Net profit from ordinary Activities after Tax (9-10)	1,416	1,284	1,094	3.884	3,143	4,567	
	Extraordinary items		92	- 1,001	92	-	(44	
	Net Profit for the Period (11+12)	1,416	1,376	1,094	3,976	3,143	4,524	
12	Paid-up Equity Share Capital of Rs.10/- each.	1,211	1,211	1,211	1,211	1,211	1,211	
13	Reserves & Surplus (excluding revaluation reserves)		-		-		19,550	
	Earning per share (of Rs. 10 /- each) (not annualised)						7 m	
	Basic & Diluted (Rs.)	11.69	11.36	9.04	32.83	25.96	37.38	





Manufacturers of : Bulk Drugs & Chemicals

Corporate Office: Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel.: 022-2407 2249 / 2401 9025 (30 Lines)

Fax: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com Website: www.aartidrugs.com

			Quarter Ended			Nine Months Ended	
Sr.	Particulars	31st Dec 2013	30th Sep 2013	31st Dec 2012	31st Dec 2013	31st Dec 2012	31st March 2013
No.	7511117	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
PARTII		(vidines)	(Addition)	(Padilida)	(Abbited)	(Abdited)	(Audited

PA	RT II						
A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding	C177 178 178 178 178 178 178 178 178 178					
	-Number of Shares	4,901,063	5,024,311	5,188,057	4,901,063	5,188,057	5,154,122
	-Percentage of Total Shareholding	40.48	41.49	42.85	40.48	42.85	42.5
2	Promoters & Promoter Group shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares( as a % of the	Nil	Nil	Nil	Nil	Nil	Nil
	total shareholding of promoter and promoter group)			1500		20000	
	-Percentage of shares( as a % of the	Nil	Nil	Nii	Nil	Nil	Nil
	total Share capital of the company)					08071.7	
	b) Non-encumbered						
	- Number of Shares	7,207,487	7,084,239	6,920,493	7,207,487	6,920,493	6,954,428
	-Percentage of shares( as a % of the total Shareholding	100	100	100	100	100	100
	of promoter and promoter group)			130000		2000	
	-Percentage of shares( as a % of the total	59.52	58.51	57.15	59.52	57.15	57.43
	Share capital of the company)	1920000		EASOE:		0.000000	

В	INVESTOR COMPLAINTS	Quarter Ended 31st Dec., 2013
	Pending at the beginning of the quarter	0
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the guarter	0

#### Notes

- 1 The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 31st January, 2014
- 2 The Board of Directors have declared a 2nd Interim Dividend of Rs. 4.50 per Equity shares of Rs.10/- each amounting to Rs. 5,44,88,475/- and 6th February, 2014 has been fixed as record date for payment of said interim dividend.
- 3 Company is operating as a Single Segment Company, engaged in Pharmaceuticals Business.
- 4 Four plants located in Tarapur, shut from 21.10.2013 due to notice by Pollution Control Authority, have since been fully operational during November 201
- 5 Figures for the previous period have been regrouped or rearranged wherever necessary.

For and on behalf of the Board For AARTI DRUGS LIMITED

HARSHIT M. SAVLA (JT. MANAGING DIRECTOR)

Place: Mumbai

Date: 31st January, 2014.



# PARIKH JOSHI & KOTHARE (Regd.)

## CHARTERED ACCOUNTANTS

49 / 2341, M.H.B. Colony, Gandhi Nagar, Bandra ( East ), Mumbal - 400 051.

©: +91 22 2651 5396 / 2645 1439 • Fax: +91 22 2645 5867 • E-mail: pjkbandra@yahoo.co.in • Website: www.pjkca.com

Auditor's Report On Quarterly Financial Results and Year to Date Results of AARTI DRUGS

LTD Pursuant to the Clause 41 of the Listing Agreement

To

Board of Directors of AARTI DRUGS LIMITED

We have audited the quarterly financial results of AARTI DRUGS LIMITED for the quarter ended 31st December 2013 and the year to date results for the period from 1st April 2013 to 31st December 2013, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 which, as per a clarification issued by the Ministry of Corporate Affairs, continues to apply under section 133 of the Companies Act 2013 (which has superseded section 211(3C) of the Companies Act 1956 w.e.f.12 September 2013) and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



# PARIKH JOSHI & KOTHARE CHARTERED ACCOUNTANTS

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31<sup>st</sup> December 2013 and the year to date results for the period from 1<sup>st</sup> April 2013 to 31<sup>st</sup> December 2013.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For PARIKH JOSHI & KOTHARE CHARTERED ACCOUNTANTS

Firm Registration No: 107547W

CA. TEJAS J. PARIKH

PARTNER

Membership No. 123215

Mumbai, Dated: January 31st, 2014